EQL Pharma AB (OSTO:EQL) Debt-to-Asset : 0.56 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:EQL EQL Pharma AB OSTO:EQL
38 GF Score
Price kr24.55
! 6 Warning Signs
View Full Analysis

What is EQL Pharma AB Debt-to-Asset?

EQL Pharma AB OSTO:EQL -2.58% 38 Debt-to-Asset is 0.56 as of Jun. 2026. GuruFocus rates OSTO:EQL with a GF Score™ of 38/100. The stock has 6 warning signs investors should review.

EQL Pharma AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was kr114.1 Mil. EQL Pharma AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was kr345.6 Mil. EQL Pharma AB's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2026 was kr819.5 Mil. EQL Pharma AB's debt to asset for the quarter that ended in Jun. 2026 was 0.56.

EQL Pharma AB  (OSTO:EQL) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

EQL Pharma AB Debt-to-Asset Related Terms

EQL Pharma AB Debt-to-Asset Historical Data

* Premium members only.

The historical data trend for EQL Pharma AB's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

EQL Pharma AB Debt-to-Asset Chart

EQL Pharma AB Annual Data
Trend Dec16 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.01 0.31 0.56 0.54

EQL Pharma AB Quarterly Data
Jun21 Sep21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.57 0.54 0.54 0.54 0.56

OSTO:EQL vs ZTS: Debt-to-Asset Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, EQL Pharma AB's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

EQL Pharma AB Debt-to-Asset vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, EQL Pharma AB's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where EQL Pharma AB's Debt-to-Asset falls into.


OSTO:EQL
38GF Score
EQL Pharma AB OSTO:EQL
Debt-to-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

EQL Pharma AB Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

EQL Pharma AB's Debt-to-Asset for the fiscal year that ended in Mar. 2026 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(114.167 + 345.174) / 850.887
=0.54

EQL Pharma AB's Debt-to-Asset for the quarter that ended in Jun. 2026 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(114.077 + 345.616) / 819.521
=0.56

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Asset →
What does a Debt-to-Asset of 0.56 mean?
EQL Pharma AB (OSTO:EQL) has a Debt-to-Asset of 0.56 as of Jun. 2026. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on EQL Pharma AB and its competitors.
Is EQL Pharma AB's Debt-to-Asset too high?
EQL Pharma AB's current Debt-to-Asset is 0.56. Overall, EQL Pharma AB has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does EQL Pharma AB's Debt-to-Asset compare to ZTS?
EQL Pharma AB's Debt-to-Asset of 0.56 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Asset for a Drug Manufacturers company?
A good Debt-to-Asset depends on the Drug Manufacturers industry context. However, Debt-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Asset mean?
A high Debt-to-Asset can signal that a stock is expensive relative to its fundamentals. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on EQL Pharma AB and its competitors. EQL Pharma AB's current Debt-to-Asset is 0.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EQL Pharma AB stock overvalued right now?
EQL Pharma AB (OSTO:EQL) has a current Debt-to-Asset of 0.56. The current Debt-to-Asset is 0.56. EQL Pharma AB's overall GF Score™ is 38/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Asset calculated?
Debt-to-Asset is calculated from a company's financial statements. For EQL Pharma AB (OSTO:EQL), the current Debt-to-Asset is 0.56 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

EQL Pharma AB Business Description

Other Exchanges 7JK:Germany
Address Stortorget 1, 3rd Floor, Lund, SWE, 222 23
EQL Pharma AB is a pharmaceutical company focused on efficiently and thoughtfully developing and marketing generic drugs. The company operates in one segment, which is medicine. Its niche generics are divided into four parts based on four sales and marketing models: Retail, Hospital, Branded, and Tests. EQL Pharma specializes in identifying, developing, and selling generics, i.e., medicines that are medically equivalent to originator medicines. The company operates in Sweden, Denmark, Norway, Finland, the rest of Europe, and outside Europe, generating the majority of its revenue from Sweden.
38GF Score

Get the complete analysis for OSTO:EQL

Debt-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr24.55
Price